[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Chamberlain MC, Glantz MJ: Cerebrospinal fluid-disseminated meningioma. Cancer; 2005 Apr 1;103(7):1427-30
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebrospinal fluid-disseminated meningioma.
  • All patients had undergone prior surgery (range, one to five surgeries; median, two surgeries), radiotherapy (involved-field radiotherapy in seven patients and stereotactic radiotherapy in six patients), and chemotherapy (hydroxyurea in eight patients).
  • Multiple sites of metastases were seen in all patients and were both within the nervous system (subarachnoid or ventricular tumor: intracranial in eight patients, spinal cord in four patients) and extraneural (subcutaneous, cervical lymph nodes, orbit, or pulmonary in five patients).
  • Treatment utilized both systemic chemotherapy (temozolomide in four patients, irinotecan in three patients, hydroxyurea in three patients, interferon-alpha in two patients, and doxorubicin plus ifosfamide in one patient) and intraventricular chemotherapy (liposomal cytosine arabinoside in seven patients, thiotepa in one patient, and busulfan in one patient).
  • RESULTS: Treatment-related toxicity was seen in eight patients, including chemical meningitis in eight patients (Grade 2), neutropenia in five patients (Grade 2 in four patients and Grade 3 in one patient), fatigue in one patient (Grade 2), and gastrointestinal toxicity in one patient (Grade 2).
  • The median survival was 5.5 months, and 3 patients were alive with disease at the time of last follow-up.
  • CONCLUSIONS: The treatment of CSF-disseminated meningioma, although feasible and comparatively nontoxic, was associated with modest outcomes despite combined systemic and intraventricular chemotherapy.
  • [MeSH-major] Meningioma / secondary
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Brain Neoplasms / pathology. Brain Neoplasms / secondary. Central Nervous System Neoplasms / secondary. Cerebrospinal Fluid / cytology. Female. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Skin Neoplasms / secondary. Spinal Cord Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 15690330.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Delgado-López PD, Martín-Velasco V, Castilla-Díez JM, Fernández-Arconada O, Corrales-García EM, Galacho-Harnero A, Rodríguez-Salazar A, Pérez-Mies B: Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature. Neurocirugia (Astur); 2006 Jun;17(3):240-9
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature.
  • Lung and intraabdominal organs are most frequently affected.
  • To our knowledge, this is the first description of a total en bloc spondylectomy through a posterior approach for the treatment of an intraosseous metastatic meningioma to the eleventh dorsal vertebra.
  • CASE REPORT: In March 1996, a 37 year-old male underwent surgical resection for a left occipital intraventricular benign meningioma (WHO I).
  • By the end on 2003 he developed progressively invalidating dorsolumbar pain.
  • The pathological specimen was identified as adenocarcinoma and he initiated chemotherapy.
  • Advice from a second pathologist was seeked, who suggested the diagnosis of intraosseous meningioma.
  • In June 2004 he underwent T11 total en bloc spondylectomy (Tomita's procedure), fusion with bone and calcium substitute-filled stackable carbon-fiber cages, and T9 to L1 transpedicular screw fixation.
  • Definite pathology: benign meningioma (WHO I).
  • [MeSH-major] Meningioma / pathology. Orthopedic Procedures / methods. Spinal Neoplasms / secondary. Spinal Neoplasms / surgery. Thoracic Vertebrae

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855782.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


3. Chang KH, Song CE, Seo JH, Yeo SW: Solitary metastasis of bronchogenic adenocarcinoma to the internal auditory canal: a case report. J Korean Med Sci; 2009 Dec;24(6):1227-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 58-yr-old man who had received 6-cycle of chemotherapy under diagnosis of non-small cell lung carcinoma (T4N2M0) two years ago was referred to our department with vertigo, right-sided facial paralysis and right-sided hearing loss.
  • A provisional diagnosis of vestibular schwannoma or meningioma involving right IAC was made from magnetic resonance imaging.
  • The patient died 9 months after surgery from extensive brain metastasis despite postoperative radiation therapy.
  • In patients with a previous history of treatment of malignancy elsewhere in the body, the possibility of IAC metastasis must be considered when an IAC lesion is detected.
  • [MeSH-major] Adenocarcinoma / pathology. Ear Neoplasms / secondary. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Feb;126(2):209-14 [10680873.001]
  • [Cites] Neuroradiology. 2001 Jan;43(1):52-7 [11214649.001]
  • [Cites] Arq Neuropsiquiatr. 2002 Sep;60(3-A):639-42 [12244407.001]
  • [Cites] J Laryngol Otol. 1985 Sep;99(9):839-46 [2995524.001]
  • [Cites] Am J Otolaryngol. 2006 May-Jun;27(3):214-6 [16647989.001]
  • [Cites] AJNR Am J Neuroradiol. 1993 Jan-Feb;14(1):99-106 [8427116.001]
  • [Cites] J Laryngol Otol. 1993 Dec;107(12):1087-98 [8288995.001]
  • [Cites] Acta Otolaryngol. 2004 Dec;124(10):1117-23 [15768802.001]
  • [Cites] J Laryngol Otol. 2005 Dec;119(12):1010-2 [16354372.001]
  • [Cites] Am J Otol. 1989 Jul;10(4):297-300 [2801895.001]
  • (PMID = 19949690.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2775882
  • [Keywords] NOTNLM ; Adenocarcinoma / Internal Auditory Canal / Lung Neoplasms / Neoplasm Metastasis
  •  go-up   go-down


Advertisement
4. Nayak L, Abrey LE, Iwamoto FM: Intracranial dural metastases. Cancer; 2009 May 1;115(9):1947-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of the current study was to evaluate the demographics, clinical presentation, imaging, treatment, and prognosis of patients with IDM.
  • RESULTS: : Sixty-one percent of the patients were women; the median age at diagnosis was 59 years, the median Karnofsky performance scale (KPS) at diagnosis was 80, and the median time to IDM diagnosis from initial cancer diagnosis was 37 months.
  • Eighty-three percent of patients had active systemic disease at the time of IDM diagnosis.
  • A lower KPS and lung cancer were associated with worse overall survival.
  • Surgical resection and chemotherapy improved progression-free survival, but only resection was found to be associated with improved overall survival.
  • KPS and status of systemic cancer should guide treatment decisions.
  • [MeSH-major] Dura Mater. Meningeal Neoplasms / secondary. Meningioma / secondary
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Disease-Free Survival. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241421.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Lusis E, Gutmann DH: Meningioma: an update. Curr Opin Neurol; 2004 Dec;17(6):687-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma: an update.
  • This review will focus on recent advances and their significance for future research and treatment.
  • Radiosurgery is an effective adjuvant therapy against meningioma; however, no effective chemotherapy exists.
  • In addition to histologic grading and estimates of the extent of resection, biomarkers, such as progesterone receptor, cyclooxygenase 2, S100A5 and ornithine decarboxylase may be useful in predicting tumor recurrence and/or progression potential in patients with meningioma.
  • On the genetic level, cytogenetic losses on chromosomes 1, 7, 10 and 14 and telomerase activation are observed in clinically aggressive meningioma, whereas monosomy 22 is a common early molecular event in tumor formation.
  • Several candidate growth regulatory genes have been identified, including the Neurofibromatosis 2 (NF2), Tumor Suppressor in Lung Cancer-1 (TSLC1), Protein 4.1B, p53/MDM2 and S6-Kinase genes.
  • The roles of these genes in meningioma formation and progression, as well as the clinical implications of these genetic changes, are discussed.
  • SUMMARY: The recent insights into the molecular biology and genetics of meningioma provide new avenues for basic science research aimed at understanding the mechanisms underlying meningioma formation and malignant progression.
  • These advances may be useful in improving our ability to predict clinical outcome and developing targeted therapies to improve outcomes in patients with clinically aggressive meningiomas.
  • [MeSH-major] Meningeal Neoplasms / enzymology. Meningeal Neoplasms / genetics. Meningioma / enzymology. Meningioma / genetics

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15542977.001).
  • [ISSN] 1350-7540
  • [Journal-full-title] Current opinion in neurology
  • [ISO-abbreviation] Curr. Opin. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 38
  •  go-up   go-down


6. Picquet J, Valo I, Jousset Y, Enon B: Primary pulmonary meningioma first suspected of being a lung metastasis. Ann Thorac Surg; 2005 Apr;79(4):1407-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pulmonary meningioma first suspected of being a lung metastasis.
  • We describe a primary pulmonary meningioma first suspected of being a metastasis because it presented as a solitary subpleural pulmonary nodule in a patient with breast cancer.
  • The absence of radiographic change after 6 months of chemotherapy led to resection of the breast and lung lesions.
  • A complete central nervous system evaluation eliminated other locations of meningioma, allowing the diagnosis of primary pulmonary meningioma.
  • [MeSH-major] Lung Neoplasms / diagnosis. Meningioma / diagnosis

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15797095.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


7. Incarbone M, Ceresoli GL, Di Tommaso L, Cappuzzo F, Inzirillo F, Infante M, Alloisio M: Primary pulmonary meningioma: report of a case and review of the literature. Lung Cancer; 2008 Dec;62(3):401-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pulmonary meningioma: report of a case and review of the literature.
  • Primary pulmonary meningioma (PPM) is a rare disease and usually presents as a solitary pulmonary nodule (SPN).
  • These lesions are mostly benign, but malignant PPMs have been reported, and primary lung cancer or metastasis may be suspected on imaging.
  • Diagnostic work-up included radiological chest study and in 3 cases positron emission tomography (PET) showing increased uptake, highly suspicious for malignancy.
  • Indeed, 8 patients (32%) were overtreated with major thoracic surgical resection or with chemotherapy.
  • When feasible, pulmonary wedge resection by video-assisted thoracic surgery (VATS) including intra-operative histological examination is the most suitable approach to determine the diagnosis and the volume of pulmonary resection.
  • [MeSH-major] Lung Neoplasms / diagnosis. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Solitary Pulmonary Nodule / diagnosis
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Positron-Emission Tomography / methods. Radiopharmaceuticals. Thoracic Surgery, Video-Assisted. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486986.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


8. Oyoshi T, Nakayama M, Hirano H, Shimokawa S, Kuratsu J: Intracranial dural metastasis of mediastinal seminoma--case report. Neurol Med Chir (Tokyo); 2000 Aug;40(8):423-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 24-year-old male presented with a rare intracranial dural metastasis from a mediastinal germ cell tumor infiltrating the superior vena cava, pericardium, ascending aorta, and lung.
  • One year after the radiotherapy, magnetic resonance imaging revealed a right parasagittal tumor mimicking a meningioma.
  • Two cycles of chemotherapy with carboplatin and etoposide were then performed, and the residual tumor almost completely disappeared.
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Seminoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10979266.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


9. Benedetto N, Perrini P, Scollato A, Buccoliero AM, Di Lorenzo N: Intracranial meningioma containing metastatic colon carcinoma. Acta Neurochir (Wien); 2007 Aug;149(8):799-803; discussion 803
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial meningioma containing metastatic colon carcinoma.
  • Meningioma is the most common intracranial tumour to host metastases, the majority of which arise from breast and lung cancers.
  • We present the first report of a colonic cancer metastasis within an intracranial meningioma.A 76-year-old woman presented with a one month history of partial seizures.
  • Her medical history included resection of an adenocarcinoma of the descending colon followed by adjuvant chemotherapy 1 year before our evaluation.
  • The pathological examination demonstrated a mixture of fibrous meningioma and colloid adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Colonic Neoplasms / surgery. Meningeal Neoplasms / secondary. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasms, Second Primary / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660939.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


10. Travitzky M, Libson E, Nemirovsky I, Hadas I, Gabizon A: Doxil-induced regression of pleuro-pulmonary metastases in a patient with malignant meningioma. Anticancer Drugs; 2003 Mar;14(3):247-50
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Doxil-induced regression of pleuro-pulmonary metastases in a patient with malignant meningioma.
  • Metastatic meningioma is a rare disease, which has no effective chemotherapy.
  • We report on a treatment of this condition with Doxil, a liposomal doxorubicin formulation.
  • A 60-year-old woman with massive pleuro-pulmonary metastases from recurrent cranial meningioma was treated with Doxil (50-37.5 mg/m2) for 18 months with near-complete resolution of metastases and disappearance of pleural fluid.
  • The patient remains in near-complete response for 6 months after treatment discontinuation.
  • This is the first report on an effective chemotherapy in a patient with typical metastatic meningioma.
  • The exact mechanism accounting for such an effective drug action is not clear, but may be related to a particularly high microvascular permeability to the liposome carriers in these metastatic lesions.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Doxorubicin / therapeutic use. Lung Neoplasms / drug therapy. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Lippincott Williams & Wilkins
  • (PMID = 12634620.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin
  •  go-up   go-down


11. Andersson U, Malmer B, Bergenheim AT, Brännström T, Henriksson R: Heterogeneity in the expression of markers for drug resistance in brain tumors. Clin Neuropathol; 2004 Jan-Feb;23(1):21-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneity in the expression of markers for drug resistance in brain tumors.
  • This study evaluated the immunohistochemical expression and distribution of P-glycoprotein (Pgp), multidrug resistance protein (MRP1), lung resistance protein (LRP) and O6 methylguanine-DNA methyltransferase (MGMT) in low- and high-grade astrocytoma, oligodendroglioma and in different subgroups of meningioma.
  • In meningioma, a heterogeneous expression of Pgp, MRP1, LRP and MGMT was seen with the most prominent staining localized to the capillary endothelium.
  • Pgp was significantly more often overexpressed (p < 0.05) in transitional compared to meningothelial meningioma.
  • The marked heterogeneity in the expression suggests that analysis of these factors can be of importance in the selection of individualized chemotherapy, regardless of tumor type.
  • [MeSH-major] Brain Neoplasms / metabolism. Glioma / metabolism. Meningioma / metabolism. Neoplasm Proteins / metabolism. O(6)-Methylguanine-DNA Methyltransferase / metabolism. P-Glycoprotein / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Brain / metabolism. Child. Child, Preschool. Drug Resistance, Neoplasm / physiology. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14986930.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


12. Biglia N, Gadducci A, Ponzone R, Roagna R, Sismondi P: Hormone replacement therapy in cancer survivors. Maturitas; 2004 Aug 20;48(4):333-46
MedlinePlus Health Information. consumer health - Menopause.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hormone replacement therapy in cancer survivors.
  • OBJECTIVE: Thousands of women are treated each year for cancer; many of these are already in menopause, while other younger patients will go into early menopause due to surgery, or chemotherapy, or the need for radiotherapy to the pelvic region.
  • The purpose of this paper is to review biological and clinical evidences in favour and against HRT use in the different tumours and to propose an algorithm that can help choosing the treatment for the single woman.
  • RESULTS: With the exception of meningioma, breast and endometrial cancer, there is no biological evidence that HRT may increase recurrence risk.
  • CONCLUSIONS: Even if a cautious approach to hormonal-dependent neoplasias is fully comprehensible and the available alternative treatment should be taken into greater consideration, the reticence to prescribe HRT in women previously treated for other non hormone-related tumours has neither a biological nor a clinical basis.
  • [MeSH-major] Hormone Replacement Therapy. Menopause / drug effects. Neoplasms / drug therapy. Survivors
  • [MeSH-minor] Breast Neoplasms / drug therapy. Colonic Neoplasms / drug therapy. Endometrial Neoplasms / drug therapy. Female. Humans. Kidney Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Melanoma / drug therapy. Meningioma / drug therapy. Ovarian Neoplasms / drug therapy. Risk Factors. Thyroid Neoplasms / drug therapy. Urinary Bladder Neoplasms / drug therapy. Uterine Cervical Neoplasms / drug therapy. Vulvar Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15283925.001).
  • [ISSN] 0378-5122
  • [Journal-full-title] Maturitas
  • [ISO-abbreviation] Maturitas
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] Ireland
  • [Number-of-references] 134
  •  go-up   go-down


13. Ng E, Ilsen PF: Orbital metastases. Optometry; 2010 Dec;81(12):647-57

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiotherapy and chemotherapy were initiated, but the patient died shortly afterward.
  • An area of the retina appeared elevated; ophthalmic B-scan and computed tomography of the orbits confirmed the presence of a mass, determined to be metastatic lung carcinoma to the right orbit.
  • A course of radiotherapy was initiated, but the patient died 3 days after completing therapy.
  • However, a computed tomography scan showed a new meningioma in the same orbit, and treatment was started.
  • Prognosis can be poor, and thus treatment is sometimes palliative in nature, intending to slow the progression of the disease instead of providing a cure.
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Adenocarcinoma / therapy. Aged. Blepharoptosis / etiology. Diplopia / etiology. Esophageal Neoplasms / pathology. Exophthalmos / etiology. Humans. Lung Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Magnetic Resonance Imaging. Male. Meningioma / pathology. Middle Aged. Neoplasms, Second Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Optometric Association. All rights reserved.
  • (PMID = 21111373.001).
  • [ISSN] 1558-1527
  • [Journal-full-title] Optometry (St. Louis, Mo.)
  • [ISO-abbreviation] Optometry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Tabacu E, Galie N, Mitrea M, Stoicescu I, Zăvoianu C: [Multiple primary cancers with different localizations and histologic types. Clinical case]. Pneumologia; 2003 Jan-Mar;52(1):51-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple primary cancers with different localizations and histologic types. Clinical case].
  • The authors describe the case of male patient of 46 years old, which was diagnosticated with 4 cancers of different localization and histopathological types in the course of 6 years.
  • In chronological order these 4 neoplazias were: the Hodgkin's disease with mixed cellularity, the malign parieto-frontal right meningioma, a Grawitz renal tumor and a lung adenocarcinoma with bilateral lung and pleural metastasis.
  • For both cerebral and renal tumors the patient was given a surgical treatment and for the Hodgkin's disease and lung cancer given chemotherapy and cobalt therapy.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / therapy. Hodgkin Disease / pathology. Hodgkin Disease / therapy. Humans. Kidney Neoplasms / pathology. Kidney Neoplasms / therapy. Lung Neoplasms / pathology. Lung Neoplasms / therapy. Male. Meningeal Neoplasms / pathology. Meningeal Neoplasms / therapy. Meningioma / pathology. Meningioma / therapy. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14702702.001).
  • [ISSN] 2067-2993
  • [Journal-full-title] Pneumologia (Bucharest, Romania)
  • [ISO-abbreviation] Pneumologia
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


15. Moss J, DeCastro R, Patronas NJ, Taveira-DaSilva A: Meningiomas in lymphangioleiomyomatosis. JAMA; 2001 Oct 17;286(15):1879-81
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Lymphangioleiomyomatosis (LAM), a cystic lung disease associated with progressive respiratory failure, is found predominantly in women of childbearing age and therefore has been treated with progesterone and other hormonal agents.
  • However, meningiomas have progesterone receptors, and progesterone is believed to be a mitogen for meningioma cells in culture.
  • DESIGN AND SETTING: Analysis of results from ongoing routine screening protocols initiated in December 1995 at the National Heart, Lung, and Blood Institute.
  • PATIENTS: Two hundred fifty women with sporadic LAM who were referred for screening by magnetic resonance imaging (MRI) and/or computed tomography (CT) of the brain.
  • In view of the lack of a documented effect of progesterone on progression of lung disease in LAM and the reported mitogenic response of meningiomas to progesterone, we recommend that the drug not be given to LAM patients with an MRI result consistent with diagnosis of meningioma.

  • Genetic Alliance. consumer health - Lymphangioleiomyomatosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JAMA. 2002 Mar 20;287(11):1397-8 [11903021.001]
  • (PMID = 11597290.001).
  • [ISSN] 0098-7484
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


16. Powles T, Robinson D, Shamash J, Moller H, Tranter N, Oliver T: The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol; 2008 Mar;19(3):443-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis.
  • In this study, we address this issue for the first time.
  • It also helps in planning long-term follow-up for patients receiving this form of treatment.

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2008 Mar;19(3):407-8 [18227108.001]
  • (PMID = 18048383.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; BG3F62OND5 / Carboplatin
  •  go-up   go-down


17. Tews DS, Fleissner C, Tiziani B, Gaumann AK: Intrinsic expression of drug resistance-associated factors in meningiomas. Appl Immunohistochem Mol Morphol; 2001 Sep;9(3):242-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrinsic expression of drug resistance-associated factors in meningiomas.
  • The role of chemotherapy, however, remains controversial, although there is evidence that meningiomas respond well to adjuvant chemotherapy.
  • A major obstacle in chemotherapy remains drug resistance with reduced cellular drug accumulation through membrane efflux pumps, drug detoxification, and alterations in drug target specificity.
  • In 84 classic, atypical, and malignant meningiomas, the immunohistochemical expression profile of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP), lung resistance-related protein (LRP), metallothionein, and topoisomerase IIalpha were studied.
  • All types of meningiomas showed constant expression of P-gp, LRP, MRP, and topoisomerase IIalpha; metallothionein was found in 67% of the tumors, especially in atypical and malignant meningiomas.
  • P-gp, LRP, and topoisomerase IIalpha were strongly expressed by normal and neoplastic vessels, which may confer to impaired penetration of therapeutic agents through the blood-brain and blood-tumor barrier.
  • These intrinsic drug resistances indicate that successful chemotherapy may require additional inhibition of these factors to be a promising approach in the management of meningiomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11556752.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Neoplasm Proteins
  •  go-up   go-down


18. Hatta R, Nambu Y, Suzuki S, Tachi Y, Oikawa T, Nakagawa K, Tuchihara K, Tobe T, Osanai K, Toga H, Takahashi K, Ohya N: [A case of atypical pulmonary carcinoid accompanying skin metastasis]. Nihon Kokyuki Gakkai Zasshi; 2004 Apr;42(4):357-61
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of atypical pulmonary carcinoid accompanying skin metastasis].
  • A 73-year-old woman underwent cranial surgery in 1999 after receiving a diagnosis of suspected malignant meningioma.
  • She began complaining of headache 2 years postoperatively, and around the same time, she noticed a painful skin tumor.
  • Systemic examination demonstrated a primary lesion in the left lung.
  • Pulmonary, skin and bone biopsy samples exhibited the same pathological findings as those of the atypical pulmonary carcinoid tumor.
  • EP therapy (etoposide + carboplatin) and CAV therapy (cyclophosphamide + doxorubicin + vincristin) were administered, but there was no clinical response.
  • The patient is currently doing well without chemotherapy and is being followed by the Outpatient Department.
  • [MeSH-major] Carcinoid Tumor / pathology. Carcinoid Tumor / secondary. Lung Neoplasms / pathology. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15114855.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Pozzati E, Zucchelli M, Schiavina M, Contini P, Foschini MP: Rapid growth and regression of intracranial meningiomas in lymphangioleiomyomatosis: case report. Surg Neurol; 2007 Dec;68(6):671-4; discussion 674-5
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Lymphangioleiomyomatosis is a progressive interstitial lung disease that affects young women.
  • It has been suggested that estrogens play a role in its evolution, and progesterone therapy is often provided in these cases.
  • The significance of this association and the hormonal treatment of the disease are discussed.
  • [MeSH-major] Lymphangioleiomyomatosis / drug therapy. Meningeal Neoplasms / chemically induced. Meningioma / chemically induced. Progesterone / adverse effects. Progestins / adverse effects

  • Genetic Alliance. consumer health - Lymphangioleiomyomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17586005.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Progestins; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


20. Bushnell D, Menda Y, O'Dorisio T, Madsen M, Miller S, Carlisle T, Squires S, Kahn D, Walkner W, Connolly M, O'Dorisio S, Karwal M, Ponto J, Bouterfa H: Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment. Cancer Biother Radiopharm; 2004 Feb;19(1):35-41
Hazardous Substances Data Bank. (L)-ARGININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
  • During each treatment two liters of an amino acid solution containing arginine and lysine (Aminosyn II 7%, Abbott Laboratories, Abbott Park, IL) were infused IV over 4 hours.
  • Thirty-seven subjects received a total of 89 90Y-SMT 487 treatments.
  • [MeSH-major] Amino Acids / administration & dosage. Amino Acids / pharmacology. Kidney / drug effects. Octreotide / administration & dosage. Octreotide / analogs & derivatives. Octreotide / therapeutic use. Yttrium Radioisotopes / administration & dosage. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Adult. Aged. Arginine / administration & dosage. Arginine / pharmacology. Carcinoid Tumor / metabolism. Carcinoid Tumor / radiotherapy. Female. Humans. Infusions, Intravenous. Lung Neoplasms / metabolism. Lung Neoplasms / radiotherapy. Lysine / administration & dosage. Lysine / pharmacology. Male. Meningioma / metabolism. Meningioma / radiotherapy. Middle Aged. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / radiotherapy. Radiopharmaceuticals / administration & dosage. Radiopharmaceuticals / adverse effects. Radiopharmaceuticals / pharmacokinetics. Radiopharmaceuticals / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. L-Lysine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15068609.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Radiopharmaceuticals; 0 / Yttrium Radioisotopes; 94ZLA3W45F / Arginine; K3Z4F929H6 / Lysine; RWM8CCW8GP / Octreotide; U194AS08HZ / Edotreotide
  •  go-up   go-down


21. Yamamoto T, Nakai K, Matsumura A: Boron neutron capture therapy for glioblastoma. Cancer Lett; 2008 Apr 18;262(2):143-52
Hazardous Substances Data Bank. BORON, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Boron neutron capture therapy for glioblastoma.
  • Boron neutron capture therapy (BNCT) theoretically allows the preferential destruction of tumor cells while sparing the normal tissue, even if the cells have microscopically spread to the surrounding normal brain.
  • Recent clinical studies of BNCT have focused on high-grade glioma and cutaneous melanoma; however, cerebral metastasis of melanoma, anaplastic meningioma, head and neck tumor, and lung and liver metastasis have been investigated as potential candidates for BNCT.
  • Improved tumor-targeting boron compounds and optimized administration methods, improved boron drug delivery systems, development of a hospital-based neutron source, and/or other combination modalities will enhance the therapeutic effectiveness of BNCT in the future.
  • [MeSH-major] Boron Neutron Capture Therapy. Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy
  • [MeSH-minor] Boron / therapeutic use. Clinical Trials as Topic. Forecasting. Humans. Photons / therapeutic use. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18313207.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] N9E3X5056Q / Boron
  • [Number-of-references] 77
  •  go-up   go-down






Advertisement